Arctic Bioscience announces encouraging top-line results from the HeROPA clinical study
The HeROPA phase 2b study in mild-to-moderate psoriasis show encouraging results on key secondary endpoint with increasing durable efficacy up…
0,408€
25,77%
Echtzeit-Aktienkurs Arctic Bioscience AS
Bid:
Ask:
Nachrichten zur Arctic Bioscience AS Aktie
Arctic Bioscience – Board approval of share capital increase related to conversion of debt
Reference is made to the stock exchange release published by Arctic Bioscience 30th January 2025 regarding exercise of right to…
Arctic Bioscience – Exercise of right to convert debt and issuance of shares
With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. A…
Arctic Bioscience – Primary insiders participating in convertible loan facility
Reference is made to the stock exchange release from earlier today, 13[th] January 2025, regarding new funding, including a convertible…
Arctic Bioscience – funded to cash positive
· Arctic Bioscience is now funded through a NOK 30 million loan facility.
· Strong 30% y/y growth in…
Arctic Bioscience – Minutes of the Extraordinary General Meeting
An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 19 November 2024 at 10:00 (CET). All the items…
Arctic Bioscience – Notice of Extraordinary General Meeting on 19 November 2024
An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 19 November 2024 at 10:00 (CET), as a…
Arctic Bioscience – Q3 2024 Operational update
Highlights Q3 2024:
· The HeROPA 6-month read-out showed an effect close to the assumed effect level in the…
Arctic Bioscience – Mandatory notification of trade
Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK…
Arctic Bioscience – Presentation for today’s webcast
With reference to yesterday’s stock exchange release regarding webcast to be hosted today at 12:00 CET to present the results…
Arctic Bioscience – New cellular research showing anti-psoriatic effects
Arctic Bioscience are today presenting new research on cells at the EADV congress in Amsterdam. These cellular data show anti-psoriatic…
Arctic Bioscience – Invitation to presentation of half year 2024 results
Arctic Bioscience will publish its financial results for the first half year of 2024 on Thursday 29[th] of August, at…
Arctic Bioscience – New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells
Arctic Bioscience are today presenting a new data on anti-inflammatory cellular functions of herring roe oil at the 9th European…
Arctic Bioscience – Q1 2024 Operational update – Progress according to plan
Highlights Q1 2024:
· The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as…
Arctic Bioscience – Minutes of the Annual General Meeting
The Annual General Meeting of Arctic Bioscience AS was held Friday 26 April 2024 at 11:00 (CET). All the items…
Arctic Bioscience – Notice of Annual General Meeting on 26 April 2024
Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting.
Shareholders…
Arctic Bioscience – Annual report 2023
Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements. The report…
Arctic Bioscience – Extension of share options to members of management group
The Board of Directors of Arctic Bioscience AS has resolved to extend the share option agreements for the following members…
Arctic Bioscience – Q4 2023 Operational update – Foundation for an exciting 2024
Highlights Q4 2023:
· The HeROPA clinical trial fully recruited in January 2024
· Available liquidity end of…
Arctic Bioscience – Treatment start for 519 patients in the HeROPA-study
With reference to the stock exchange announcement from 17. January 2024 which reported that the HeROPA phase IIb clinical trial…